Literature DB >> 2140330

Efficacy and safety of clarithromycin versus josamycin in the treatment of hospitalized patients with bacterial pneumonia.

G Straneo1, G Scarpazza.   

Abstract

The efficacy and safety of 500 mg clarithromycin and 1000 mg josamycin both given twice daily for a maximum of 14 days were compared in the treatment of 72 hospitalized patients with bacterial pneumonia. The predominant pathogens isolated were Streptococcus pneumoniae and Staphylococcus aureus. Clinical success was reported for 91.5% of patients treated with clarithromycin and for 87.0% of those treated with josamycin. Eradication of the causative pathogen was noted in 85.7% of patients receiving clarithromycin and in 90% of those receiving josamycin. Adverse events considered probably to relate to therapy were experienced by 2% of patients treated with clarithromycin and by 12.5% of those treated with josamycin; one patient treated with josamycin was withdrawn because of severe nausea and moderate vomiting. Treatment with clarithromycin at half the dosage of josamycin was found to have comparable efficacy and to be associated with a lower incidence of adverse events.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2140330     DOI: 10.1177/030006059001800211

Source DB:  PubMed          Journal:  J Int Med Res        ISSN: 0300-0605            Impact factor:   1.671


  8 in total

Review 1.  Formulary management of macrolide antibiotics.

Authors:  D R Guay
Journal:  Pharmacoeconomics       Date:  1995-12       Impact factor: 4.981

Review 2.  Clarithromycin. A review of its efficacy in the treatment of respiratory tract infections in immunocompetent patients.

Authors:  H D Langtry; R N Brogden
Journal:  Drugs       Date:  1997-06       Impact factor: 9.546

Review 3.  Intracellular concentrations of antibacterial agents and related clinical implications.

Authors:  J D Butts
Journal:  Clin Pharmacokinet       Date:  1994-07       Impact factor: 6.447

Review 4.  Clarithromycin clinical pharmacokinetics.

Authors:  F Fraschini; F Scaglione; G Demartini
Journal:  Clin Pharmacokinet       Date:  1993-09       Impact factor: 6.447

Review 5.  Clarithromycin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential.

Authors:  D H Peters; S P Clissold
Journal:  Drugs       Date:  1992-07       Impact factor: 9.546

Review 6.  Overview of the tolerability profile of clarithromycin in preclinical and clinical trials.

Authors:  D R Guay; D R Patterson; N Seipman; J C Craft
Journal:  Drug Saf       Date:  1993-05       Impact factor: 5.606

7.  Burden of pneumococcal disease among adults in Southern Europe (Spain, Portugal, Italy, and Greece): a systematic review and meta-analysis.

Authors:  Adoración Navarro-Torné; Eva Agostina Montuori; Vasiliki Kossyvaki; Cristina Méndez
Journal:  Hum Vaccin Immunother       Date:  2021-06-09       Impact factor: 4.526

Review 8.  Antibiotics for hospital-acquired pneumonia in neonates and children.

Authors:  Steven Kwasi Korang; Chiara Nava; Sutharshini Punniyamoorthy Mohana; Ulrikka Nygaard; Janus C Jakobsen
Journal:  Cochrane Database Syst Rev       Date:  2021-11-02
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.